Geron Corp. GERN
Biotechnology: Pharmaceutical Preparations · IPO 1996 · data as of November 13, 2026
Geron Corp. (GERN) is a healthcare company listed in the US with a market value of about $623M. In the twelve months to September 30, 2026 it had revenue of $218M and net income of -$48M, a net margin of -22.0%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -45%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 59% below the current price.
About Geron
Geron is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 1996. Revenue went from $1M in 2014 to $237000 in 2023, a decline of about 16.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 75% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | — | — | $237000 | $596000 | $1M | $253000 | $460000 | $1M | $1M | $6M |
| Net income | -$48M | -$84M | -$175M | -$184M | -$142M | -$116M | -$76M | -$69M | -$27M | -$28M | -$30M |
| Free cash flow | -$91M | — | -$219M | -$169M | -$128M | -$96M | -$67M | -$44M | -$21M | — | -$18M |
| EPS (diluted) | $-0.08 | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | $-0.36 | $-0.15 | $-0.18 | $-0.19 |
| Net margin | -22.0% | — | — | -77690.7% | -23808.9% | -8335.4% | -29888.1% | -14901.7% | -2534.4% | -2621.2% | -479.3% |
| ROIC | — | -13.4% | -34.1% | -45.9% | -80.6% | -49.6% | -25.2% | -41.6% | -13.8% | -22.3% | -19.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $3.50, 262% above the current price; targets range from $2.50 to $5.00; the consensus rating is “Buy”; expected EPS is $-0.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Geron stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 59% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Geron pay a dividend?
Not currently.
Is Geron a good stock to buy?
We do not give buy or sell advice. Geron scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.